



National Lieutenant Governors Association

RESOLUTION IN SUPPORT OF NLGA'S YEAR-LONG COMMITMENT TO PROMOTE INCREASED DIVERSITY PARTICIPATION IN CLINICAL TRIALS

1
2
3 **Whereas**, the U.S. and the biopharmaceutical industry lead the world in developing new medicines and prescription medicines
4 which yield critical advances against serious disease, helping people live longer, healthier lives; and
5 **Whereas**, continued advances in such innovation will be key in addressing future health care challenges, in helping patients lead
6 better lives, and in curbing health care costs to states and territories; and
7 **Whereas**, clinical trials of new medicines are a vitally important and legally required part of the drug development and approval
8 process; and
9 **Whereas**, successful completion of the clinical trials process is required to show the Food and Drug Administration (FDA) that
10 an investigational drug is safe and effective so it can be made available to a broader patient population; and
11 **Whereas**, clinical trials are the primary route by which patients can voluntarily participate in the drug development process,
12 receive access to unapproved investigational medicines, and contribute to the collection of safety and efficacy data necessary for
13 FDA approval; and
14 **Whereas**, biopharmaceutical research companies are conducting more than 5,400 clinical trials for new medicines in collaboration
15 with clinical research centers, university medical schools, and hospitals; and
16 **Whereas**, these clinical trials have a significant economic impact in the states and communities, beyond the economic advantages
17 of improved public health; and
18 **Whereas**, a key to successful clinical trials is a diverse and robust volunteer participation;
19 **Whereas**, minority communities are underrepresented in the clinical trials; and
20 **Whereas**, despite comprising 12 percent of the U.S. population, African Americans make up only 5 percent of clinical trial
21 participants. Hispanics represent 16 percent of the U.S. population, but only 1 percent of clinical trial participants¹; and
22 **Whereas**, according to the FDA, increased diversity in clinical trials could help researchers find better ways to fight diseases that
23 disproportionately impact certain populations, and may be important for the safe and effective use of new therapies; and
24 **Whereas**, participation in a clinical trial not only may benefit the patient, but may also benefit future patients by helping further
25 medical innovations that positively affect various ethnic and racial communities and all people; and
26 **Whereas**, without the patients that volunteer to participate in clinical trials, the development of these treatments would not be
27 possible;

28 **NOW LET IT RESOLVED**, that the NLGA encourages increased education and awareness among legislators, policymakers,
29 patients and providers about the clinical trial process and the need for recruitment and participation of diverse patient
30 populations; and

31 **BE IT FURTHER RESOLVED**, that the NLGA will support this effort by assisting lieutenant governors in engaging
32 constituents through the diversity in clinical trials NLGA awareness campaign "Be the Cure;" and

33 **BE IT FURTHER RESOLVED**, the members of the National Lieutenant Governors Association (NLGA) are spreading the
34 word about the need for diversity enrollment in clinical trials and the value and benefits of same, and

35 **BE IT FURTHER RESOLVED**, NLGA will make information on increasing diversity enrollment in clinical trials available to
36 as many states and territories as possible, and

37 **BE IT FURTHER RESOLVED**, NLGA will maintain an educational web site on the topic, and

38 **BE IT FURTHER RESOLVED**, we can increase diversity participation in clinical trials. Pass information to someone you
39 know and be the cure.

Sponsors: Lt. Governor Matt Michels, South Dakota (R) and Lt. Governor Nancy Wyman, Connecticut (D); Additional Co-Sponsors: Lt. Governor Jeff Colyer, KS; Secretary of State David Bernier, PR; Lt. Governor Kim Reynolds, IA; Lt. Governor Shan Tsutsui, HI; Lt. Governor Angela McLean, MT; Lt. Governor Sue Ellspermann, IN; Lt. Governor Osbert Potter, VI; Lt. Governor Daniel McKee, RI; Lt. Governor Kathy Hochul, NY

¹ The Society for Women's Health Research United States Food and Drug Administration Office of Women's Health. "Dialogues on Diversifying Clinical Trials." 2011. Available from: <http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM334959.pdf> [Accessed 2013 Oct 10].